Global Post-Traumatic Stress Disorder (PTSD) Market, By Product (Antidepressants, Cognitive Therapy, Anti-Anxiety Drugs, Exposure Therapy, Eye Movement Desensitization And Reprocessing (EMDR) and PSTD therapeutics), Application (Children and Adult), End Use (Hospitals and Clinics) - Industry Trends and Forecast to 2030.
Post-Traumatic Stress Disorder (PTSD) Market Analysis and Size
The global PTSD market has been experiencing steady growth and is expected to continue expanding. The increasing prevalence of PTSD, coupled with growing awareness and diagnosis rates, are driving the market growth. Factors such as rising traumatic events, military deployments, natural disasters, and terrorist attacks contribute to the demand for PTSD treatments.
Data Bridge Market Research analyses that the global post-traumatic stress disorder (PTSD) market which was USD 750.30 Million in 2022, would rocket up to USD 1,037.95 Million by 2030, and is expected to undergo a CAGR of 4.1% during the forecast period. “Antidepressants” dominates the product segment of the global (PTSD) market owing to the increasing investment in healthcare. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Post-Traumatic Stress Disorder (PTSD) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Antidepressants, Cognitive Therapy, Anti-Anxiety Drugs, Exposure Therapy, Eye Movement Desensitization and Reprocessing (EMDR) and PSTD therapeutics), Application (Children and Adult), End Use (Hospitals and Clinics)
|
|
Countries Covered
|
(U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa)
|
|
Market Players Covered
|
GlaxoSmithKline plc.(U.K.), Pfizer Inc.(U.S.), Eli Lilly and Company (U.S.), H. Lundbeck A/S (Denmark), Azevan Pharmaceuticals, Inc. (U.S.), Marinus Pharmaceuticals, Inc.(U.S.), Tonix Pharmaceuticals Holding Corp.(U.S.), Bionomics (Australia), Greenstone LLC (U.S.), Mylan NV(U.S.), Otsuka Pharmaceutical Co., Ltd (Japan), Prometheon Pharma, LLC.(U.S.), Ligand Pharmaceuticals Incorporated (U.S.), Lycera (U.S.), JSC Valenta Pharm.(Russia), Nuvo Pharmaceuticals Inc.(Canada), Zhenxiang Electromechanical Technology (Shanghai) Co., Ltd.(China), AstraZeneca (U.K.), Neurocrine Biosciences Inc.(U.S.)
|
|
Market Opportunities
|
|
Market Definition
The global PTSD market includes pharmaceuticals, psychotherapeutic interventions, digital health solutions, diagnostic tools, and other supportive services that contribute to the prevention, diagnosis, and treatment of PTSD. The market encompasses various stakeholders such as pharmaceutical companies, mental health service providers, research organizations, government bodies, and advocacy groups working together to address the impact of PTSD and improve the lives of individuals affected by the disorder.
Global Post-Traumatic Stress Disorder (PTSD) Market Dynamics
Drivers
- Rising awareness of PTSD symptoms
There is a growing awareness of mental health issues, including PTSD, among the general public, healthcare professionals, and policymakers. Increased awareness leads to early detection and intervention, creating a higher demand for effective treatments and interventions. Public campaigns, educational initiatives, and media attention help reduce stigma and encourage individuals to seek help for their PTSD symptoms.
- Government Initiatives
Governments and public health organizations worldwide have recognized the significant impact of PTSD on individuals and society. They have implemented initiatives, policies, and funding support to improve PTSD care, promote research, and enhance mental health services. Government initiatives drive market growth by providing resources, raising awareness, and improving access to PTSD treatments.
Opportunity
- Advancements in personalized medicines
Advancements in genetics and biomarker research offer opportunities for personalized medicine approaches in PTSD management. Identifying genetic and molecular markers associated with PTSD susceptibility and treatment response can help tailor interventions to individual patients. This approach has the potential to improve treatment outcomes and minimize adverse effects by targeting specific biological pathways and optimizing therapy based on patients' unique characteristics.
Furthermore, the rising collaboration, merger, and acquisition among the market players will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Additionally, the rising number of market players will further expand the market's growth rate in the future.
Restraint/Challenge
- High Cost Associated with The Product Manufacturing
On the other hand, the high cost associated with product manufacturing is expected to obstruct market growth. Also, the disruption in the supply chain industry has the potential to challenge the market’s growth. Also, the lack of favorable reimbursement scenarios and technology penetration in the developing economies, and the lack of suitable infrastructure are projected to challenge the market in the forecast period of 2023-2030.
This global post-traumatic stress disorder (PTSD) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Global Post-Traumatic Stress Disorder (PTSD) Market, contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Recent Development
- In 2021, Tonix Pharmaceuticals received Fast Track designation from the U.S. FDA for its investigational drug TNX-102 SL for the treatment of PTSD
- In 2020, AstraZeneca entered into a collaboration with Vanderbilt University to develop and commercialize compounds targeting the corticotropin-releasing factor 1 (CRF1) receptor for the potential treatment of PTSD and other mental health disorders.
Global Post-Traumatic Stress Disorder (PTSD) Market Scope
The global (PTSD) market is segmented on the basis of product, application, and end users. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.
Product
- Antidepressants
- Cognitive Therapy
- Anti-Anxiety Drugs
- Exposure Therapy
- Eye Movement Desensitization and Reprocessing (EMDR)
- PSTD therapeutics
Application
- Children
- Adult
End Use
- Hospitals
- Clinics
Global Post-Traumatic Stress Disorder (PTSD) Market Regional Analysis/Insights
Global post-traumatic stress disorder (PTSD) market is analyzed, and market size insights and trends are provided by product, application, and end use as referenced above.
The countries covered in the global Post-Traumatic Stress Disorder (PTSD) market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa.
North America is expected to dominate the market due to rising healthcare costs, increased R & D, and trending technological advancements.
Asia-Pacific is expected to witness the fastest growth during the forecast period of 2023 to 2030 because of the rising strategic initiatives by the key market players and favorable government initiatives in the region.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The PTSD market also provides you with a detailed market analysis for every country’s growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the market, the impact of technology using life line curves, and changes in healthcare regulatory scenarios and their impact on the market. The data is available for the historic period 2015-2021
Competitive Landscape and Post-Traumatic Stress Disorder (PTSD) Market Share Analysis
The market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to) market.
Some of the major players operating in the post-traumatic stress disorder (PTSD) market are:
- GlaxoSmithKline plc. (U.K.)
- Pfizer Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- H. Lundbeck A/S (Denmark)
- Azevan Pharmaceuticals, Inc. (U.S.)
- Marinus Pharmaceuticals, Inc. (U.S.)
- Tonix Pharmaceuticals Holding Corp. (U.S.)
- Bionomics (Australia)
- Greenstone LLC (U.S.)
- Mylan NV(U.S.)
- Otsuka Pharmaceutical Co., Ltd (Japan)
- Prometheon Pharma, LLC. (U.S.)
- Ligand Pharmaceuticals Incorporated (U.S.)
- Lycera (U.S.)
- JSC Valenta Pharm. (Russia)
- Nuvo Pharmaceuticals Inc. (Canada)
- Zhenxiang Electromechanical Technology (Shanghai) Co., Ltd. (China)
- AstraZeneca (U.K.)
- Neurocrine Biosciences Inc. (U.S.)
SKU-